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ABSTRACT
Macroautophagy/autophagy is a conserved transport pathway where targeted structures are seques-
tered by phagophores, which mature into autophagosomes, and then delivered into lysosomes for
degradation. Autophagy is involved in the pathophysiology of numerous diseases and its modulation is
beneficial for the outcome of numerous specific diseases. Several lysosomal inhibitors such as bafilo-
mycin A1 (BafA1), protease inhibitors and chloroquine (CQ), have been used interchangeably to block
autophagy in in vitro experiments assuming that they all primarily block lysosomal degradation. Among
them, only CQ and its derivate hydroxychloroquine (HCQ) are FDA-approved drugs and are thus
currently the principal compounds used in clinical trials aimed to treat tumors through autophagy
inhibition. However, the precise mechanism of how CQ blocks autophagy remains to be firmly demon-
strated. In this study, we focus on how CQ inhibits autophagy and directly compare its effects to those of
BafA1. We show that CQ mainly inhibits autophagy by impairing autophagosome fusion with lysosomes
rather than by affecting the acidity and/or degradative activity of this organelle. Furthermore, CQ
induces an autophagy-independent severe disorganization of the Golgi and endo-lysosomal systems,
which might contribute to the fusion impairment. Strikingly, HCQ-treated mice also show a Golgi
disorganization in kidney and intestinal tissues. Altogether, our data reveal that CQ and HCQ are not
bona fide surrogates for other types of late stage lysosomal inhibitors for in vivo experiments. Moreover,
the multiple cellular alterations caused by CQ and HCQ call for caution when interpreting results
obtained by blocking autophagy with this drug.
ARTICLE HISTORY
Received 2 October 2017
Revised 1 May 2018








Autophagy is an evolutionarily conserved transport pathway
crucial to maintain cellular homeostasis through the seques-
tration, delivery and degradation of unwanted proteins,
macromolecular complexes and organelles into lysosomes
[1–3]. This process has been implicated in several pathologies,
including cancer, lysosomal disorders, muscle dystrophies,
neurodegeneration, and inflammatory diseases [1,4].
Autophagy is characterized by the formation of transient
sequestering structures termed phagophores, which enwrap
the cytoplasmic components destined for turnover and
mature into double-membrane vesicles called autophago-
somes that fuse with lysosomes, allowing cargo degradation
[3,5]. The biogenesis of an autophagosome is orchestrated by
the so-called autophagy-related (ATG) proteins, which act in
a hierarchical order to first generate the phagophore, and then
expand it into an autophagosome [6]. ATG proteins are
divided in 5 functional clusters based on their molecular
roles and interactions. The ULK complex, the ATG9A cycling
system and the autophagy-specific class III phosphatidylino-
sitol 3-kinase (PtdIns3K) complex are key in generating the
phagophore upon induction of autophagy [7]. PtdIns3K, in
particular, generates the PtdIns3P (phosphatiylinositol-3-
phosphate) on phagophore membranes, which is required to
promote the binding of other ATG factors such as the WIPI
proteins and ZFYVE1/DFCP1 [8], but also some of the com-
ponents of the 2 ubiquitin-like conjugation systems compos-
ing the 2 other functional clusters that are essential for
expanding and closing the phagophore [7]. Complete autop-
hagosomes fuse with lysosomes to form autolysosomes
through a process that is tightly regulated by SNARE proteins
such as STX17 (syntaxin 17) and SNAP29, RAB GTPases,
tethering complexes such as the HOPS, and other fac-
tors [9,10].
Autophagy is a highly dynamic pathway and therefore
steady-state measurements, such as assessment of expression
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levels of autophagy marker proteins including MAP1LC3/LC3
(microtubule associated protein 1 light chain 3) and SQSTM1/
p62 are inconclusive [11]. The turnover of these proteins has
to be artificially blocked in order to accurately quantify the
amplitude of the autophagic flux [11]. Although the knock-
down of proteins involved in the fusion between autophago-
somes and lysosomes such as STX17 could be used at least in
cell culture experiments, pharmacological inhibition is more
kinetically controllable, and is the most frequently employed
strategy for both in vitro and in vivo studies. The most widely
employed chemicals that inhibit the last stage of autophagy
are chloroquine (CQ), bafilomycin A1 (BafA1), and lysosomal
protease inhibitor cocktails [11]. Whereas the mode of action
of both BafA1 and lysosomal protease inhibitors is well estab-
lished, that of CQ remains largely unknown. CQ was origin-
ally discovered and used to treat malaria, and subsequently
inflammatory diseases [12,13]. CQ is a weak base and there-
fore it can raise the pH of cellular compartments. This has led
to the assumption that CQ blocks the autophagic flux through
the same mechanism as BafA1, which increases lysosomal pH
and thus inhibits the activity of resident hydrolases [14–16]. It
remains unclear, however, whether CQ is indeed interchange-
able with BafA1 and protease inhibitors to block the last stage
of autophagy.
The discovery that modulation of autophagy has the potential
of delaying the onset of several pathologies, has led to the necessity
to pharmacologically interfere with this pathway [17]. Inhibition
of autophagy in particular, appears to be beneficial to treat specific
types of tumors, chronic obstructive pulmonary diseases, neonatal
asphyxia and defined inflammatory diseases [17]. Although novel
compounds have been recently developed to specifically inhibit
ATG components such as ULK1 and PIK3C3/VPS34 [18–21],
these drugs do not exclusively affect autophagy and, more impor-
tantly, they are not yet licensed for clinical trials. As a result, CQ
and hydroxychloroquine (HCQ), a derivative of CQ, remain the
only autophagy inhibitors that are approved by the Food and
Drug Administration (FDA) [22]. Successful clinical trials have
shown that CQ and especially HCQ, enhance the potential of
combinatorial anti-cancer therapies by sensitizing the tumor
cells (NCT00969306, https://clinicaltrials.gov/ct2/results?term=
autophagy+and+cancer&Search=Apply&recrs=e&age_v=
&gndr=&type=&rslt=), although it remains unclear whether this
is due to autophagy inhibition [23–25].
In this study, we investigated whether CQ inhibits autop-
hagy through the same mechanism as other lysosomal inhibi-
tors, in particular BafA1, by using high-content
immunofluorescence microscopy, electron microscopy and
functional autophagy assays. Although highly upregulated by
nutrient deprivation, autophagy proceeds at basal levels in
almost all tissues, carrying out numerous housekeeping func-
tions [1]. Modulation of basal autophagy is especially relevant
for clinical studies and therefore we investigated the effects of
CQ and BafA1 under normal growth conditions. We found
that CQ severely affects the endo-lysosomal system and the
Golgi complex in vitro and in vivo, thereby probably impair-
ing the basal autophagic flux by decreasing autophagosome-
lysosome fusion, and not by inhibiting lysosomal degradation
capacity as BafA1 does. Although treatments with both CQ
and BafA1 ultimately cause a block of the autophagic flux, we
show that the intracellular changes that are caused by these 2
compounds are profoundly different. As a result, the conse-
quences for cells and tissues in in vitro and in in vivo studies
as well, are greatly different. Our investigation thus shows that
CQ is not a bona fide surrogate for BafA1 (or protease inhi-
bitors), and this must be borne in mind when interpreting
results and evaluating possible side effects in both in vivo
studies and clinical trials.
Results
CQ affects the morphology of degradative compartments
differently than other lysosomal inhibitors
Autophagy terminates with the degradation of the autophagoso-
mal content in the lysosomes. In order to get more insight on the
effect of CQ on these organelles, we analyzed the subcellular
distribution of LAMP1, a marker protein for late endosomal
compartments and lysosomes [26,27], by immunofluorescence
microscopy. This analysis was performed under basal growing
conditions in 2 different cell lines, i.e. U2OS (Figure 1, Figure S1)
and HeLa (Figure S1) cells, to exclude cell-specific effects. We
chose commonly used concentrations of CQ and BafA1, i.e.
100 µM and 100 nM, respectively, and exposed U2OS and HeLa
cells to these compounds for 5 h before processing them for
immunofluorescence microscopy (Figures 1(A,B) and S1(A)).
Automated high-content quantification of the LAMP1 staining
showed a slight increase in the area of LAMP1-positive structures
in BafA1-treated U2OS and the same tendency in HeLa cells
(Figure 1(A,B) and S1(A)). CQ treatment also tended to increase
the area of LAMP1-positive structures, and this increase wasmore
pronounced in both cell lines (Figure 1(A,B) and S1(A)).
As both BafA1 and CQ are supposed to alter the lysosomal
pH, we qualitatively assessed the acidity of lysosomes over
time by fluorescence microscopy using the pH-sensitive lyso-
somal dye LysoTracker Red. As expected from an inhibitor of
the vacuolar proton pump [28], BafA1 treatment decreased
the acidity of lysosomes as it led to a rapid decrease of
LysoTracker Red puncta staining in both cell lines (Figure 1
(C,D) and S1(B)). CQ, in contrast, did not decrease
LysoTracker Red puncta staining over time in U2OS cells or
after 5 h of treatment in HeLa cells. On the contrary and in
agreement with the LAMP1 analysis (Figure 1(A,B) and S1
(A)), the measured area of LysoTracker Red-positive struc-
tures tended to be much larger at the 5 h time point after CQ
treatment compared to control or BafA1-treated cells
(Figure 1(C,D) and S1(B)). The progressive increase of the
puncta area over time indicates that the enlargement of
LysoTracker Red-positive compartments emerges from a pro-
longed treatment with CQ (Figure 1(D)).
Because there are discrepancies in the literature about
whether or not CQ raises the lysosomal pH [29,30], and our
data indicated that a concentration of 100 µM had no major
effect (Figure 1(C,D) and S1(B)), we assessed the lysosomal
acidity in U2OS cells exposed to increasing concentrations of
CQ using the LysoTracker Red dye (Figure S1(C)).
Surprisingly, LysoTracker Red-positive puncta were present
in cells treated with CQ at concentrations ranging from 25 to
200 µM (Figure S1(C)), but also at concentrations of 400 and
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800 µM when cells started to display clear signs of stress (data
not shown). In contrast, BafA1 caused a decrease in the area of
LysoTracker Red-positive puncta per cell at concentrations
between 25 nM and 1.6 µM (data not shown, Figure S1(C)).
To determine whether these 2 compounds have the same
effects on cellular degradative compartments (DGCs), we
examined the morphology of cells treated with 100 µM CQ
or 100 nM BafA1 for 5 h by electron microscopy (EM).
Because CQ and BafA1 alter the autophagic flux, we first
inspected autophagosomes in our electron microscopy pre-
parations. We found that HeLa and U2OS cells exposed to
these 2 compounds displayed an increased number of autop-
hagosomes per cell section (Figure 2(A,B) and S2(A,B)). Next,
we examined the DGCs, e.g. lysosomes, autolysosomes and
amphisomes, which are all characterized by an amorphous
electron-dense content. We decided to group these organelles
in a single category because it is difficult to distinguish them,
especially upon treatment with compounds interfering with
lysosomal degradation [31,32]. Although late endosomes also
have degradative activity, we did not group them within
DGCs because they are morphologically distinguishable.
We observed a major morphological difference between the 2
treatments. In BafA1-treated cells, cytoplasmic components
could still be detected in the lumen of DGCs (Figure 2(C) and
S2(C)), which indicates that BafA1 inhibits degradation within
these organelles as expected. Furthermore, DGCs also increased
in size especially in the U2OS cells compared to the control cells
(Figures 2(C) and S3(A,E)). The DGCs of cells exposed to CQ,
however, looked different. First, we did not observe intact cyto-
plasmic material within the DGCs in either U2OS or HeLa cells,
but rather a condensed amorphous content similar to untreated
cells (Figures 2(C) and S2(C,E)). Second, in 39% of U2OS cells
and 65% of HeLa cells, we observed the additional presence of
large vacuolar DGCs (i.e., vDGCs), which are characterized by a
clear content and the presence of limited lumenal material
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Figure 1. Quantitative automated fluorescence microscopy analysis revealed significant major differences between BafA1 and CQ treatments on DGCs. U2OS cells
were treated with the vector (ctrl/0 h), 100 µM CQ or 100 nM BafA1 for 5 h, or in a time course manner between 0 and 5 h, before processing for
immunofluorescence microscopy. Images were acquired and analyzed automatically using the Cellomics Arrayscan. (A) Staining of the preparations with anti-
LAMP1 antibodies. (B) Quantification of the LAMP1 puncta area per cell (arbitrary units) from the immunofluorescence images such as for the examples shown in
panel A. (C) Cells treated for the indicated times, were incubated with LysoTracker Red for 1 h before being processed for fluorescence microscopy. (D) Quantification
of the LAMP1 puncta area per cell (arbitrary units) from images such as the examples depicted in panel C. All data are presented relative to the control at 0 h (fold).
Error bars represent standard deviations (SD) of 3 independent experiments. * or ** symbols indicate significant differences of p < 0.05 and p < 0.01, respectively.
Scale bars: 20 µm.
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frequently observed in HeLa cells exposed to shorter CQ treat-
ment, i.e. 1 h or 2 h, compared to cells treated for 5 h with the
same drug (data not shown). Furthermore, immuno-electron
microscopy (IEM) analysis of cells exposed to CQ for 2 h showed
that the content of LAMP2-labeled DGCs was condensed, con-
firming the result obtained with conventional EM. Moreover,
IEM revealed that the larger structures positive for LAMP pro-
teins that we observed by immunofluorescence microscopy,
were clusters of DGCs and not the vDGCs that we observed
after prolonged treatments (Figure S2(E)). This observation is in
line with the LysoTracker Red analysis (Figure 1(D)), which
suggests the formation of large organelles was due to a gradual
effect caused by prolonged CQ treatment and that vDGCs are
not present at earlier time points.
Because of this major difference in the impact of these 2
compounds on DGCs, we repeated the ultrastructural analysis
in cells exposed to another lysosomal inhibitor, i.e. a cocktail
of lysosomal protease inhibitors composed of E64, pepstatin
and leupeptin [11]. DGCs in U2OS and HeLa cells treated
with this mixture looked very similar to the ones treated with
BafA1 (Figure S2(C,D), S3(A–D)). We concluded that CQ has

































































Figure 2. Quantitative EM analysis highlights the morphological differences in the DGCs induced by CQ and BafA1. U2OS cells were treated with the vector (water;
ctrl), 100 µM CQ or 100 nM BafA1 for 5 h, before processing for EM as described in Materials and Methods. (A) Representative images of the observed
autophagosomes (AP). Scale bars: 250 nm. (B) Quantification of the number of AP per cell section. (C) Representative image of DGCs detected in the preparations.
Enlargements of the insets highlighted with a white square in the image on left row, are shown in the right row. Arrow highlights DGCs. Scale bar: 1 µm. (D)
Statistical evaluation of the number of DGCs per cell section, which were subdivided in regular (DGCs, i.e. lysosomes, amphisomes and autolysosomes) and large
vacuolar DGCs (vDGCs). EM preparations were quantified as described in Materials and Methods. M, mitochondria; ER, endoplasmic reticulum; N, nucleus; PM, plasma
membrane; DGCs, regular degradative compartments; vDGCs, vacuolar degradative compartments.
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compounds known for direct inhibition of the degradative
capacity of these organelles.
Altogether, these data revealed that BafA1 and CQ have
profoundly different effects on the morphology and the acid-
ity of DGCs.
CQ disorganizes the Golgi complex and the endo-
lysosomal system in vitro and in vivo
CQ can affect functions of the endo-lysosomal system [13,33].
We thus explored the distribution of selected endo-lysosomal
protein markers upon treatment with either 100 µM CQ or
100 nM BafA1 by immunofluorescence microscopy. Although
its localization remained unaltered in the presence of BafA1,
the early endosome peripheral membrane protein EEA1 [34]
changed its distribution, and its signals became fainter over
time when cells were exposed to CQ (Figure 3(A) and S1(D)).
TGOLN2/TGN46, a trans-Golgi network (TGN) marker pro-
tein [35], also changed distribution over time in the presence
of CQ, unlike that which was observed in untreated and
BafA1-treated cells (Figure 3(B)). In particular, CQ caused a
redistribution of TGOLN2 puncta from perinuclear concen-
trations [36] to puncta dispersed throughout the cytoplasm,
resulting in an increase in the number of TGOLN2 puncta per
cell (Figure 3(B)). A similar change in the Golgi complex
organization in CQ-treated cells was also observed when
either the cis-Golgi marker protein GOLGA2/GM130 [37]
(Figure 3(C)) or the ARCN1/delta subunit of the COPI coat
complex involved in retrograde transport at the Golgi [38]
were analyzed (Figure S4(A)). Consistently, we found at the
ultrastructural level that the Golgi complexes in CQ-treated
cells were disorganized and many more vesicles could be
observed in the proximal surrounding area (Figure S5(A,B),
CQ panels). In contrast, BafA1 did not alter the Golgi stack
organization but rather the morphology of the stacks them-
selves. The Golgi lumens were swollen in HeLa cells and less
pronouncedly in U2OS cells compared to those in the control
cells, something also observed to a lesser extent in CQ-treated


















































































Figure 3. CQ but not BafA1, has a significant impact on the endolysosomal system and the Golgi complex. U2OS cells were exposed to the vector (ctrl/0 h), 100 µM
CQ or 100 nM BafA1 for 5 h or in a time-course manner between 0 and 5 h, before processing for immunofluorescence microcopy, and being automatically imaged
and analyzed. Subcellular distribution of EEA1 (A), TGOLN2 (B), GOLGA2 (C) and M6PR (D), which was quantified by determining either the puncta area per cell
(arbitrary units) (A) or the number of puncta per cell (B-D). All data are presented relative to the control at 0 h (fold). Error bars represent SD of 3 (A and D), 5 (B) or 4
(C) independent experiments. Images of panels A, B and D were acquired using the Cellomics Arrayscan and those of panel C using the TissueFAXS. Symbols *, ** and
*** indicate significant differences of p < 0.05, p < 0.01 and p < 0.001. Scale bars: 20 µm.
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(mannose-6-phosphate receptor, cation dependent), a protein
cycling between the TGN and endosomes [39,40]. In agree-
ment with the other observations, M6PR changed distribution
in the presence of CQ, becoming more dispersed in punctate
structures, whereas BafA1 had no effect on the subcellular
localization of this protein (Figure 3(D)).
Because both drugs interfere with the autophagic flux, we
were wondering whether the phenotypes observed in CQ-
treated cells were due to an impairment of canonical autop-
hagy. Thus, we depleted either ATG7 or ATG13 in U2OS cells
(Figure S4(B)) before treating the cells with CQ or BafA1 and
quantitatively assessing LAMP2-positive DGCs or the Golgi
using TGOLN2 and GOLGA2 as marker proteins (Figure S4
(C–E)). ATG7 or ATG13 depletion did not influence the
alterations caused by CQ on LAMP2-positive DGCs or the
Golgi organization. In fact, we still observed an enlargement
of LAMP2-positive DGCs (Figure S4(C)) and the redistribu-
tion of GOLGA2 and TGOLN2 puncta from perinuclear
concentrations to puncta dispersed throughout the cytoplasm,
resulting in an increased number of TGOLN2 (Figure S4(D))
or GOLGA2 (Figure S4(E)) puncta per cell. This indicates that
the effects of CQ on the endo-lysosomal system and the Golgi
are independent from its effects on canonical autophagy.
CQ and its derivate HCQ are frequently used in in vivo
experiments to block autophagy and are currently being tested
in clinical trials to treat specific cancers. Therefore, we
explored whether the effects of CQ on the Golgi organization
that we were observing in vitro could also be detected in vivo,
in HCQ-treated mice. We first tested whether CQ and HCQ
had the same capacity of blocking autophagy in mouse cells in
vitro. To determine this, we treated mouse embryonic fibro-
blasts (MEFs) with different concentration of CQ and HCQ
and measured SQSTM1 puncta accumulation. This experi-
ment confirmed that both compounds block autophagy simi-
larly in a concentration-dependent manner (Figure S6(A)).
For the in vivo study, we therefore opted to use HCQ because
it is predominantly used in clinical trials. To test the in vivo
effect of HCQ on Golgi organization, we injected C57BL/
6JOlaHsd mice daily with 60 mg/kg HCQ [41] intraperitone-
ally and sacrificed 3 animals 24 h after the first injection
(24 h) or 24 h after the second injection (48 h). The control
group (ctrl) was injected with a saline solution. Subsequently,
we stained sections obtained from the kidneys (Figure 4(A)
and S6(B)) and the intestine (Figure 4(B) and S6(C)) with
antibodies against GOLGA2 or LC3. Interestingly, we
observed a change in the Golgi organization in kidney cells
from a more tubular/ring-like conformation in control ani-
mals to a very punctate phenotype in all the HCQ-treated
animals (Figure 4(A) and S6(B)). The Golgi staining of the
intestinal cells in the control animals was predominantly peri-
nuclear, with a triangular shape in the basal part of the cells
(Figure 4(B), ctrl). In the HCQ-treated animals we uncovered
a change in this distinct Golgi organization, i.e. after 24 h we
observed a shift in the Golgi staining towards the apical part
of the cells and after 48 h of HCQ treatment, the perinuclear
staining of the basal part of the cells almost completely dis-
appeared (Figure 4(B) and S6(C)). Importantly, we could
observe LC3 puncta accumulation in both kidney and intest-
inal tissues only after 48 h, which indicated that the effect of
HCQ on the Golgi organization is more rapid than its effect
on autophagy. These results confirm the effects of CQ/HCQ
on the Golgi organization in vivo at least in intestine and
kidneys. However, future studies are needed to determine
the functional consequences of the ultrastructural alterations.
Altogether, these results show that CQ and its derivate
HCQ severely alter the organization of the Golgi and the
endo-lysosomal system in vitro and in vivo in an autophagy-
independent manner.
CQ affects endosomal trafficking differentially depending
on the endocytosis pathway
These observations prompted us to explore whether, in addi-
tion to altering its organization, CQ also affects the function-
ality of the endo-lysosomal system. In particular, we examined
2 forms of endocytosis: receptor-mediated endocytosis by mea-
suring the trafficking and degradation of EGFR (epidermal
growth factor receptor), and fluid phase endocytosis by visua-
lizing and quantifying the uptake of BSA-TRITC (TRITC-con-
jugated bovine serum albumin) [42]. To assess effects on
receptor-mediated endocytosis, Hela cells were pre-treated
with CQ or BafA1 for 2 h before we stimulated the cells with
50 ng/ml of Alexa Fluor 555-conjugated EGF for 0 to 60 min,
and labeled DGCs with a LAMP2 antibody to visually examine
the delivery of internalized EGFR to DGCs (Figure 5(A,B)).
The LAMP2 and labeled EGF showed an increased degree of
colocalization over time in control and BafA1-treated cells.
Interestingly, the colocalization in CQ-treated cells remained
significantly lower, indicating a reduction in the endocytic
transfer of EGF to DGCs (Figure 5(B)). To determine whether
this results in an impairment of receptor degradation, we
stimulated the cells with 50 ng/ml EGF for 0 to 120 min after
2 h of pre-treatment with CQ and BafA1, and examined EGFR
levels by western blot (Figure 5(C)). As expected, EGFR levels
decreased over time in control cells. In CQ- and BafA1-treated
cells, in contrast, EGFR degradation was blocked. In the same
samples, we also observed that in all treatment conditions
EGFR became phosphorylated at position Y1068, a major
autophosphorylation site of activated EGFR [43], upon EGF
addition (Figure 5(D)). Although autophosphorylated EGFR
disappeared over time in control cells, the turnover of phos-
phorylated EGFR was slightly delayed in BafA1-treated cells
and even more retarded in cells exposed to CQ (Figure 5(D)),
indicating that CQ treatment reduces EGFR degradation by
impairing receptor-mediated endocytic transfer of this receptor
to the DGCs and might thereby misregulate EGFR signaling.
Next, we measured the cellular uptake of BSA-TRITC.
Briefly, U2OS and HeLa cells were incubated with CQ or
BafA1 for 2 h before adding BSA-TRITC for 30 min. After
this initial pulse, cells were chased for 90 min in a medium
without this fluorescent conjugate and processed for immu-
nofluorescence microscopy using antibodies against the DGCs
marker protein LAMP2 (Figures 6(A–C) and S7(A–C))
[26,27]. Quantifications revealed that endocytosed BSA-
TRITC colocalized with LAMP2 in CQ- and BafA1-treated
cells to the same extent as in control cells (Figures 6(A,B), and
S7(A,B)). Importantly, the enlarged LAMP2-positive struc-
tures observed in cells exposed to CQ were also positive for
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BSA-TRITC (Figure 6(A,C) and S7(A,C), arrows). These
results revealed that CQ treatment influences endocytosis in
a cargo- and endocytic route-dependent manner.
The result obtained from the BSA uptake experiment
raised the question as to whether the large LAMP1- and
LAMP2-positive DGCs that we observed forming upon CQ
treatment are derived from either lysosomes or other com-
partments. To address this question, we pre-labeled lyso-
somes with BSA-TRITC in both U2OS (Figure 6(D–F)) and
HeLa (Figure S7(D–F)) cells by incubating them with this
fluorescent conjugate for 30 min and then chasing it for
90 min. Subsequently, cells were exposed to CQ or BafA1
for 5 h, or left untreated before processing them for immu-
nofluorescence microscopy with anti-LAMP2 antibodies.
Untreated and BafA1-treated cells showed similar percen-
tages of colocalization between BSA-TRITC and LAMP2 in
both U2OS and HeLa cells (Figure6(D,E) and S7(D,E)). An













Figure 4. HCQ alters the Golgi organization in kidney and intestinal cells of treated mice. C57BL/6JOlaHsd mice were injected daily with 60 mg/kg HCQ or with saline
solution (ctrl) and sacrificed 24 h after the first injection (24 h) or 24 h after the second injection (48 h). Representative images of kidney cells (A) and intestinal cells
(B) stained for GOLGA2 and LC3 from one mouse are shown (images from the second and third mouse of the same groups are displayed in Figure S6). Scale bars:
10 µm.
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Importantly, the measurement of the area of individual
LAMP2- and BSA-TRITC-positive puncta, demonstrated
that the large DGCs detected in CQ-treated cells are also
positive for these 2 marker proteins (Figure 6(D), arrow, 6
(F), Figure S7(D), arrow, 7(F)).
Altogether, these results highlight that the large LAMP1- and
LAMP2-positive DGC organelles are derived from lysosomes.
Moreover, CQ does not impair all forms of endocytosis despite
the prominent alterations that it is causing to the organization of
the endo-lysosomal system.
CQ inhibits autophagosomal bulk degradation without
affecting the lysosomal acidity
BafA1 and CQ are frequently used as lysosomal inhibitors to
measure the autophagic flux [11]. Because of the differences

















































































































Figure 5. CQ impairs endocytosis-mediated degradation of EGFR. (A-B) Hela cells were exposed to 100 µM CQ or 100 nM BafA1 for 2 h, or left untreated, before being
incubated with 50 ng/ml of Alexa Fluor 555-conjugated EGF from 0 to 60 min. Cells were finally processed for immunofluorescence microscopy and stained with anti-
LAMP2 antibodies (A). (B) Quantification of the colocalization between EGF-labeled EGFR and LAMP2 puncta in the experiment shown in panel A. (C-D) Hela cells
were exposed to 100 µM CQ or 100 nM BafA1 for 2 h, or left untreated, before being incubated with 50 ng/ml EGF from 0 to 120 min. Cells were finally lysed and
protein resolved by western blot and membranes were probed with anti- EGFR (C) or anti-phospho EGFR (Y1068) (D) and anti-tubulin or anti-actin antibodies. Signals
were quantified and normalized to TUBA4A/tubulin or actin (arbitrary units). Samples in C and D were probed on the same gel, and therefore the actin bands in C
and D are identical. Data in panel C are presented relative to the control at 0 min (fold) and data in panel D are presented relative to the control at 5 min (fold). Error
bars represent the SD of 3 independent experiments. Symbols *, ** and *** indicate significant differences of p < 0.05, p < 0.01 and p < 0.001, with control cells at
the same time point. Scale bars: 10 µm.
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in lysosomal acidity and endo-lysosomal organization in CQ-
and BafA1-treated cells, we wondered whether these 2 com-
pounds block the autophagic flux through the same mechan-
ism. Therefore, we analyzed basal autophagy progression for 5
and 24 h in the presence of CQ or BafA1 by first assessing LC3
conjugation to phosphatidylethanolamine (Figure 7(A)). The
levels of this lipidated form of LC3, also known as LC3-II, are
commonly used to monitor the amount of autophagosomes
forming in the cell [44]. Increased amounts of LC3-II, how-
ever, can correlate with either an induction of autophagy or a
block at the late steps of this pathway, i.e. autophagosome
fusion with lysosomes and/or lysosomal degradation [11]. In
our experiment, we also treated U2OS cells simultaneously
with CQ and BafA1. The rationale behind this double
treatment was that if these 2 compounds inhibit the autopha-
gic flux through the same mechanisms, they would not have
an additive effect. As shown in Figure 7(A) and as expected,
CQ and BafA1 led to significantly higher levels of LC3-II
compared to control cells and those levels increased over
time. Importantly, BafA1 increased LC3-II levels more pro-
nouncedly than CQ and the co-treatment with both com-
pounds increased LC3-II cellular amounts similarly to those
of cells exclusively exposed to BafA1.
We also assessed the autophagic flux by examining the
distribution of endogenous SQSTM1 (Figure S8(A,B)), a spe-
cific cargo protein of autophagosomes, which forms aggre-
gates prior to transport [11]. As observed for LC3-II, BafA1


























































 68.3 ± 10.0 56.2 ± 13.9
BafA1  55.1 ± 8.3 49.1 ± 10.2
 61.8 ± 4.370.3 ± 3.8 
ctrl
CQ 





 41.5 ± 3.9 67.0 ± 4.3 
BafA1  53.2 ± 2.7* 65.1 ± 7.5
 60.3 ± 11.645.0 ± 5.6 
Figure 6. CQ does not impair endocytosis and endo-lysosomal trafficking of BSA but causes vacuolization of lysosomes. (A) U2OS cells were exposed to 100 µM CQ or
100 nM BafA1 for 2 h or left untreated, before being incubated with 375 nM BSA-TRITC (BSA-T) for 30 min. The cells were then washed and further incubated in the
same medium with 100 µM CQ or 100 nM BafA1 and without BSA-TRITC for 90 min. Finally, cells were processed for immunofluorescence microscopy and stained
with anti-LAMP2 antibodies. The white arrow indicates large BSA-TRITC-positive LAMP2 puncta. (B) Quantification of the colocalization between BSA-TRITC (BSA-T)
and LAMP2 puncta in the experiment shown in panel A. (C) Determination of the average size of the BSA-TRITC (BSA-T)-, LAMP2- and BSA-TRITC/LAMP2 (coloc)-
positive puncta (arbitrary units) in the experiment shown in panel A. (D) U2OS cells were incubated with 375 nM BSA-TRITC (BSA-T) for 30 min, washed and further
incubated in medium without BSA-TRITC for 90 min before being exposed to 100 µM CQ or 100 nM BafA1 for 5 h, or left untreated. Cells were subsequently prepared
for immunofluorescence microscopy and labeled with anti-LAMP2 antibodies. The white arrow indicates large BSA-TRITC-positive LAMP2 puncta. (E) Quantification of
the colocalization between BSA-TRITC (BSA-T) and LAMP2 puncta in the experiment shown in panel D. (F) Determination of the average size of the BSA-TRITC (BSA-
T)-, LAMP2- and BSA-TRITC/LAMP2 (coloc)-positive puncta (arbitrary units) in the experiment shown in panel D. All images were acquired using the DeltaVision
microscope. Data in panels C and F are presented relative to the control (folds). Error bars represent SD of 3 independent experiments. Symbols * and ** indicate
significant differences of p < 0.05 and p < 0.01, respectively. Scale bars: 10 µm.
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positive aggregates that appeared as distinct puncta, in both
U2OS and HeLa cells already after 5 h of treatment, whereas
CQ only had a less pronounced effect after 5 h (Figure S8(A,
B)). Upon prolonged treatment in U2OS cells for 24 h, the
number of SQSTM1 puncta per cell increased significantly in






































































































































































































Figure 7. CQ treatment inhibits the autophagic flux. U2OS cells were treated with 100 µM CQ or 100 nM BafA1 for 5 h or with 50 µM CQ and 100 nM BafA1, for 24 h
(A), or with 100 µM CQ or 100 nM BafA1 for 2 h (B), individually or in combination; controls were untreated cells. Cells were finally lysed and protein resolved by
western blot and membranes were probed with anti-LC3 and anti-TUBA4A/tubulin antibodies. Signals were quantified and normalized to TUBA4A/tubulin (a.u.,
arbitrary units). (C) U2OS cells were exposed to 100 nM BafA1, 100 µM CQ, 100 nM torin1 or 10 µM SAR-405 (SAR) for 2 h or 5 h, or to 20 nM BafA1, 50 µM CQ, 4 µM
SAR-405 for 24 h, as indicated, before the LDH sequestration assay was performed as described in Materials and Methods. (D) The long-lived protein turnover assay
was carried out in U2OS cells treated with 100 nM BafA1 and/or 100 µM CQ for 2 h and 5 h, or to 20 nM BafA1 and/or 50 µM CQ for 24 h, as indicated, and following
the protocol described in Materials and Methods. Error bars represent SD of 3 (A, C and D) or 5 (B) independent experiments. When not otherwise indicated, the
statistical significances were calculated to the controls for each time point in panel C and D. The symbols *, ** and *** indicate significant differences of p < 0.05,
p < 0.01 and p < 0.001, respectively.
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exposed to BafA1. Co-treatment with both chemicals
increased SQSTM1 accumulation further upon 5 h of treat-
ment, whereas 24 h co-treatment did not further enhance
SQSTM1 puncta accumulation (Figure S8(A)). In parallel,
we also tested whether the acidity of DGCs changed in CQ-
treated cells after 24 h, which could explain the significant
increase in LC3 lipidation and SQSTM1 accumulation after
prolonged treatments. However, we could still detect
LysoTracker Red puncta after 24 h of CQ exposure (Figure
S8(C)), indicating that the acidity of the DGCs did not sub-
stantially change over the course of this treatment.
Because we observed some differences in the autophagy
marker response between CQ- and BafA1- treated cells that
were more pronounced after 5 h compared to 24 h (Figure 7
(A), Figure S8(A)), we decided to examine the effects of both
drugs on LC3 lipidation upon a shorter treatment (2 h). In
this analysis, we also observed higher levels of LC3-II in cells
exposed to either CQ or BafA1, and that the combination of
the 2 drugs had an additive effect (Figure 7(B)) Altogether,
this set of experiments showed that BafA1 and CQ impair
autophagy, but their effects on conventional autophagy pro-
tein markers are different, especially at the 2-h and 5-h time
points, indicating that the primary inhibition mechanism on
the autophagic flux may be different.
We thus decided to measure more directly the autophagic
activity in cells treated with CQ and BafA1. LDH (lactate dehy-
drogenase) is a non-selective autophagosomal cargo and its
sequestration by phagophores can be employed to measure
autophagosome formation [45–47]. As expected, LDH seques-
tration strongly increased when cells were incubated with torin1
(Figure 7(C)), a strong autophagy inducer [48]. Importantly, the
LDH sequestration assay revealed that BafA1 as well as CQ
treatments for 5 and 24 h comparably increase LDH sequestra-
tion over time (Figure 7(C)). Surprisingly, however, CQ led to a
higher LDH sequestration compared to the control and BafA1-
treated cells shortly upon addition (Figures 2(h) and 7(C)),
suggesting that brief CQ treatments could stimulate autophago-
some formation. Data that we obtained by analyzing the sub-
cellular distribution of early autophagy protein markers such as
ZFYVE1 and WIPI1 (data not shown), confirmed that CQ can
stimulate an autophagic response shortly upon addition to cells
as previously suggested [29,49]. Co-treatment with the PIK3C3
inhibitor SAR405 [18] completely abolished LDH sequestration,
showing that the measured sequestration was indeed mediated
by autophagy (Figure 7(C)). We also conducted a direct mea-
surement for the autophagic flux, i.e. the long-lived protein
degradation assay [11,47] (Figure 7(D)). Importantly, this assay
confirmed that CQ and BafA1 directly or indirectly inhibit
autophagy-mediated lysosomal protein degradation because
the long-lived proteins did not undergo substantial degradation
in the presence of these drugs after both 5 and 24 h (Figure 7(D))
[47,50] and no additional effect was observed when these 2
compounds were combined. Interestingly, the degree of inhibi-
tion of protein degradation by CQ was comparable to that of
BafA1 also at the 2 h time point, showing that CQ impairs the
autophagic flux even though it stimulates autophagosome
biogenesis.
Altogether, our results revealed that although cell treat-
ment with CQ or BafA1 leads to a complete block of the
autophagic flux, CQ does not abolish lysosomal acidity and
it affects autophagy marker proteins differently than BafA1,
indicating that the autophagy inhibition mechanism of CQ is
not identical with that of BafA1.
CQ blocks the autophagic flux by impairing
autophagosome-lysosome fusion
Because our data were indicating that the autophagy inhibi-
tion mechanism of CQ is not analogous to that of BafA1, we
designed a series of specific experiments to identify which step
of autophagy is inhibited by CQ. First, we exploited a HeLa
cell line that stably expresses the mRFP-GFP-LC3 reporter
construct, i.e. HeLa mRFP-GFP-LC3, which allows measuring
the autophagic flux [44,51]. In particular, this probe makes it
possible to distinguish autophagosomes (GFP- and RFP-posi-
tive LC3 puncta, which are thus yellow) from the more acidic
autolysosomes (GFP-negative and RFP-positive LC3 puncta,
which are thus red) (Figure S8(D)). As a result, fluorescence
microscopy allows discriminating between blocks in the bio-
genesis of autophagosomes versus blocks in the fusion of
these vesicles with acidic compartments such as lysosomes
[11]. We additionally stained cells for LAMP2 because BafA1
changes the acidity of lysosomes making it impossible to
distinguish autophagosomes from autolysosomes as both are
RFP- and GFP-positive in BafA1-treated cells (Figure 8(A)
and S8(D)). Thus, inclusion of LAMP2 labeling allowed us
to study the fusion events of autophagosomes and lysosomes
even when the acidity of the lysosomes is altered.
As expected, CQ and also BafA1 treatment led to an
increase in overall RFP-LC3 puncta (Figure 8(B)). This pool
of RFP-LC3 puncta comprises cytosolic autophagosomes as
well as autolysosomes. To distinguish the population that is
cytosolic from the one that is fused with lysosomes, we exam-
ined the colocalization of RFP-LC3 with LAMP2 (Figure 8
(C)). In BafA1-treated cells, we observed a percentage of RFP-
LC3-positive autophagosomes fused with LAMP2-positive
lysosomes similar to that of the control cells at both analyzed
time points. In contrast, the percentage of RFP-LC3-positive
autophagosomes that colocalized with LAMP2-positive lyso-
somes decreased over time in cells exposed to CQ (Figure 8
(C)), leading to a concomitant augmentation of the cytosolic
amount of RFP-LC3-positive autophagosomes (Figure 8(A),
arrows). Moreover, the percentage of RFP-LC3-positive
puncta colocalizing with LAMP2-positive lysosomes was sig-
nificantly decreased by the addition of CQ to BafA1-treated
cells (Figure 8(C)), further underlining that CQ blocks the
fusion of LC3-positive autophagosomes with lysosomes. Of
note, we did not observe a GFP signal in the LAMP2-positive
lysosomes of CQ-treated cells (Figure 8(A)), confirming that
the acidity of this organelle was not altered, as the GFP-signal
of the fraction of autophagosomes that were still able to fuse
with lysosomes was quenched. Together, these data show that
CQ gradually impairs the fusion of LC3-positive autophago-
somes with LAMP2-positive lysosomes without affecting the
acidity of the latter.
Because it has been shown that CQ promotes LC3 con-
jugation on endosomes [29,49] and we indeed observed that
this compound severely affects and disorganizes components
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of the endo-lysosomal system (Figures 2(C,D), 3(A), S1(D), 2
(C–E)), we used SQSTM1 as an alternative autophagy marker
protein to study the effects of CQ on the autophagic flux. We
examined the subcellular distribution of SQSTM1 in U2OS
cells also labeled for LAMP2, to determine whether the
SQSTM1 puncta were accumulating either in the LAMP2-
decorated lysosomes (Figure 9(A), yellow arrows) or in the
cytoplasm and autophagosomes, where they are not positive
for LAMP2 (Figure 9(A), red arrows). This analysis revealed
that CQ did not increase the percentage of SQSTM1 puncta
positive for LAMP2 (Figure 9(B)). Consequently, most of the
SQSTM1 puncta were negative for LAMP2 (Figure 9(A), red
arrows) and their percentage did not decrease over time
(Figure 9(C)), confirming that CQ impairs the fusion of
autophagosomes (LAMP2-negative SQSTM1 puncta) with
lysosomes.
In contrast to CQ, BafA1 caused an almost complete colo-
calization between SQSTM1 and LAMP2 (Figure 9(B)), high-
lighting again that this compound principally blocks the
degradation in lysosomes. Interestingly, addition of CQ to
the BafA1 treatment reduced the colocalization between
SQSTM1 and LAMP2 at the 24-h time point (Figure 9(B),
24 h) and therefore increased the cytoplasmic SQSTM1 sig-
nificantly (Figure 9(C), 24 h). To show that the SQSTM1
puncta that we observed in CQ-treated cells represented
bona fide incorporations into LC3-positive autophagosomes,
we determined the colocalization degree between LC3 and
SQSTM1 puncta (Figure S8(E)). This analysis revealed that
the majority of the SQSTM1 puncta (approximately 76%) in
CQ-treated cells, were positive for LC3 and that this percen-
tage of colocalization was not significantly different from
control cells (Figure S8(E)). This result confirms that the
SQSTM1 puncta that we observed in CQ-treated cells repre-
sent autophagosomes and also shows that CQ can act partially
epistatically to BafA1 during long-term treatments.
Next, we looked at potential candidate proteins that, if
misregulated, could lead to the fusion impairment observed
in CQ-treated cells. First, we examined the localization of
ATG9A because this transmembrane protein is transported
through part of the secretory pathway, including the Golgi,
A
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Figure 8. CQ treatment inhibits autophagosome-lysosome fusion without losing lysosomal acidity. RFP-GFP-LC3 HeLa cells were treated with 100 µM CQ, 100 nM
BafA1, or a combination of BafA1 and CQ (B+ CQ) for 5 h or left untreated (ctrl). Cells were subsequently prepared for immunofluorescence microscopy and stained
with an anti-LAMP2 antibody. (A) Representative images are shown. Image stacks acquired with the DeltaVision microscope were analyzed using the Icy software and
the number of all RFP-positive puncta (the LC3 populations in the cytoplasm and in the lysosomes) (B) and the percentage of LAMP2-positive RFP-LC3 puncta (i.e.,
the population of LC3 in the lysosomes) (C) was determined. Data in panels B and C are presented relative to the control (folds). Error bars represent SD of 3
independent experiments. The symbols *, ** and *** indicate significant differences of p < 0.05, p < 0.01 and p < 0.001, respectively. Scale bars: 10 µm.
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and requires glycosylation for correct functioning [52]. We
observed that both CQ and BafA1 lead to an increase in the
number of ATG9A puncta compared to control cells (Figure
S9(A,B)), possibly due to the accumulation of autophago-
somes. However, we did not observe a defect in the delivery
of ATG9A to LC3-positive autophagosomes (Figure S9©).
Next, we investigated the 2 known autophagosomal
SNARE proteins, STX17 and SNAP29 [53], which are
required for autophagosome-lysosome fusion and exclusively
localize to complete autophagosomes but not autolysosomes
[54]. In addition to the increased number of autophagosomes
in CQ-treated cells (Figures 2, 7, 8, 9), we observed a signifi-
cant increase in the proportion of STX17-positive LC3 puncta
in CQ-treated cells compared to control or BafA1-treated cells
(Figures 9(D,E)). As expected, colocalization of STX17 and
LC3 was significantly reduced in BafA1-treated cells because
STX17 disengages from autophagosomes after fusion with
lysosomes [54]. In contrast, when we analyzed the localization
of SNAP29, which forms a complex with STX17 [53], we did
not observe an increase in SNAP29 puncta nor an enhance-
ment in its recruitment onto SQSTM1-positive autophago-
somes (Figure S9(D–F)). These results indicate that CQ does
not inhibit autophagosome-lysosome fusion by blocking the
incorporation of STX17 onto LC3-positive structures, but
instead may interfere with proper SNAP29 recruitment.
Altogether, our results have revealed that CQ inhibits the
fusion between autophagosomes and lysosomes progressively
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Figure 9. CQ treatment blocks fusion of SQSTM1-positive autophagosomes with lysosomes and leads to the accumulation of STX17 puncta. (A-C) U2OS cells were
treated with 100 µM CQ and 100 nM BafA1 for 5 h, or with 50 µM CQ and 100 nM BafA1 for 24 h, individually or in combination, or left untreated (ctrl/0 h). Cells were
finally processed for fluorescence microscopy and simultaneously labeled with antibodies against SQSTM1 and LAMP2, and images were acquired using the
DeltaVision microscope. (A) Representative images of the 24-h time point are shown. Green, red and yellow arrows highlight SQSTM1-negative LAMP2 puncta,
LAMP2-negative SQSTM1 puncta and SQSTM1-positive LAMP2 puncta, respectively. (B) The percentage of SQSTM1 puncta that colocalize with LAMP2 puncta was
determined. (C) The percentage of SQSTM1 puncta that do not colocalize with LAMP2 puncta was determined. (D-F) GFP-STX17 MEFs were treated with 100 µM CQ
or 100 nM BafA1 for 5 h, or left untreated (ctrl). Cells were finally processed for fluorescence microscopy and labeled with antibodies against LC3, before acquiring
images using the DeltaVision microscope. (D) Representative images and insets with a magnified area are shown. (E) The percentage of STX17 puncta that colocalize
with LC3 puncta was determined and expressed relative to the control (fold). Error bars represent SD of 3 independent experiments. The symbols *, ** and ***
indicate significant differences of p < 0.05, p < 0.01 and p < 0.001, respectively. Scale bars: 10 µm.
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Discussion
CQ, BafA1 and protease inhibitors are interchangeably used to
block the late stages of autophagy in in vitro studies. Although
the autophagy inhibition mechanism of both BafA1 and pro-
tease inhibitors is known, it is still unclear precisely how CQ
blocks autophagy [11]. Here, we compared the effects of CQ
and BafA1 treatments on cellular morphology, autophagy
progression and endo-lysosomal trafficking. We observed
major differences in the acidity and morphological appear-
ance of the content of the DGCs in cells exposed to BafA1 and
CQ. While BafA1-treated cells displayed clear phenotypes
associated with an inhibition of the degradation capacity of
lysosomes such as the presence of intact cytoplasm in the
lysosomal lumen and a loss of acidity, CQ-treated cells did
not present a similar profile. In particular, the content of their
DGCs looked very condensed, similar to the one observed in
non-treated cells, suggesting that these DGCs still have the
capacity of degrading the delivered material.
In line with these observations, we did not find a decrease
in LysoTracker Red-positive puncta upon CQ treatment as
previously shown [29,55–57]. Our results and other recent
studies [30,58,59], indicate that CQ does not substantially
decrease lysosomal acidity, and the lysosomes retain their
capacity to degrade delivered material. Although we cannot
exclude that CQ treatment has a different effect on lysosomal
pH depending on the cell type, one has to be careful in
interpreting signal intensities of LysoTracker Red. This dye
has often been used to estimate lysosomal pH, but
LysoTracker Red is not a pH sensor and the intensity of its
fluorescence signal does not correlate with the lysosomal pH
(https://tools.thermofisher.com/content/sfs/manuals/
mp07525.pdf); it rather gives an estimation of the acidity by
losing its fluorescence when the pH is > 6.5 [60]. Therefore,
part of the discrepancy on CQ effects on lysosomal pH might
be attributed to how the pH was estimated. Moreover, CQ
may induce a temporal elevation of lysosomal pH [30,61],
which is of a transient nature and is followed by a stable,
lasting re-acidification of the lysosomes [30]. The kinetics of
this transient phase may also differ from cell type to cell type.
Treatment with CQ and other lysosomotropic cationic
drugs leads to the formation of large vacuole-like structures
that are formed due to osmotic imbalance [62]. We also
observed these vacuolar structures, i.e. vDGCs, in cells
exposed to CQ and our data suggest that they are derived
from lysosomes. Furthermore, our EM analyses indicate that
these vDGCs are not formed instantly upon CQ treatment but
are rather a consequence of prolonged exposure to this com-
pound that eventually leads to an imbalance of ion home-
ostasis, possibly causing water influx and swelling of the
lysosomes [62]. This water influx probably dilutes the lysoso-
mal content and enzymes, i.e. the lumens appear to be
deprived of proteins, but presumably their degradative capa-
city remains intact. In fact, early studies on the effect of CQ
on the autophagy pathway showed that the proteolytic activity
in isolated autophagic vesicles from cells treated with this
compound, is even higher than in the control cells, underlying
that the degradative capacity of the cells still remains intact
especially upon short exposure times to CQ [63,64]. It is
worth noting that our IEM analysis also indicate that part of
the large lysosomal structures observed by fluorescence
microscopy may represent clusters of DGCs suggesting that
CQ could also influence the subcellular distribution of these
organelles.
Although accumulation of autophagic vesicles in CQ-trea-
ted cells has already been observed in numerous early studies
[63–68], it has remained unclear whether this phenomenon
was due to an inhibition of fusion or a block in lysosomal
degradation. Our detailed examination on the step of autop-
hagy that is inhibited by CQ revealed that this compound
blocks autophagosome-lysosome fusion and not degradation
capacity of lysosomes as previously assumed [11]. BafA1, in
contrast, inhibits the degradation capacity of lysosomes by
decreasing their acidity, but it can also impair fusion between
autophagosomes and lysosomes [69,70] possibly by inhibiting
the ATP2A/SERCA (ATPase sarcoplasmic/endoplasmic reti-
culum Ca2+ transporting) pump [71]. Investigation of the 2
known autophagosomal SNARE proteins, STX17 and
SNAP29 [53], revealed that CQ allowed recruitment of
STX17, but not SNAP29, onto autophagosomes.
Alternatively, it might also be that CQ treatment leads to
the accumulation of autophagosome recognition particles,
which are distinct from autophagosomes and thereby could
prevent proper delivery of STX17 onto these double-mem-
brane vesicles [72]. Such a scenario could explain the missing
recruitment of SNAP29 to autophagosomes in CQ-treated
cells. On the one hand, our observations confirm that CQ
impairs autophagosome fusion with lysosomes. On the other
hand, they also indicate that STX17 targeting might be dysre-
gulated and this could, at least in part, be the cause of the
autophagosome-lysosome fusion impairment detected in CQ-
treated cells.
Another possible and not mutually exclusive scenario could be
that the defect in this step of autophagy is indirectly due to the
Golgi disorganization provoked by CQ, which we and others have
observed [73–75]. The Golgi is crucial for example for glycosyla-
tion and therefore the proper activation of numerous proteins
[75–78]. Although a direct functional link between Golgi and
autophagosome-lysosome fusion has not been demonstrated so
far, a few lines of evidence connect this organelle with the autop-
hagy pathway. Therefore, we have examined the subcellular dis-
tribution of ATG9A, a core ATG protein that is glycosylated and
is transported through part of the secretory pathway [52].
Although we cannot rule out an alteration of its molecular func-
tion, we could not detect a defect of ATG9A transport to phago-
phore membranes. We did find, however, a redistribution of
ARCN1/delta subunit of the COPI coat in CQ-treated cells. It
has been shown that depletion of COPI coat subunits leads to
defects in endosomal function and Golgi fragmentation, which in
turn impairs the fusion between autophagosomes and compart-
ments of the endo-lysosomal system [79]. Therefore, it is plausible
that the impact of CQ on some of the Golgi and the endosomal
functions contribute to the impairment of the fusion between
autophagosomes and lysosomes (Figure S10).
The difference in how BafA1 and CQ block the autophagic
flux is also very likely leading to different side effects when
applying these compounds for long periods because they will
influence different cellular processes. On the one hand, BafA1
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inhibits lysosomal degradation capacity and thereby nega-
tively affects the amino acid efflux from the lysosomes, pos-
sibly disturbing MTOR signaling from this organelle [80,81],
which in turn could affect a multitude of cellular pathways.
On the other hand, CQ causes an accumulation of autopha-
gosomes, which could lead to an enhanced signaling output
from autophagosomal structures [82,83]. In this regard, it has
recently been shown that the accumulation of autophago-
somes in tumor cells can compromise cell viability [84].
Interestingly, although CQ blocks the fusion of autophago-
somes with lysosomes, it appears that it differentially affects
endocytic routes. More specifically, we found that CQ impairs
receptor-mediated endocytosis and consequently the lysoso-
mal degradation of EGFR [85] but it does not impair fluid
phase endocytosis and endo-lysosomal routing of BSA [86].
Therefore, CQ is not a general inhibitor of the endo-lysoso-
mal pathway per se.
Based on our data and those from various other labora-
tories, it is evident that CQ blocks autophagic degradation
and more precisely, the delivery of sequestered cargo to the
lysosomes. Unlike BafA1 or protease inhibitors, however, this
compound causes more pronounced cellular alterations in
vitro [65] and in vivo that cannot exclusively be attributed to
lysosomal and/or autophagy inhibition (Figure S10). On the
contrary, these cellular insults may for example be the cause
of the initial autophagy stimulation (Figure 7(B,C)).
CQ was recently shown to induce LC3 conjugation onto
endosomal membranes [49] and subsequently this event was
attributed to the induction of a non-canonical form of autop-
hagy upon short-term treatment. This non-canonical form of
autophagy does not involve ATG13, ATG9A and PIK3C3/
VPS34 [29,87]. We also found that CQ indeed stimulates a
mild autophagic sequestration response for a short period,
which is in line with early studies that showed a peak in
autophagic vesicle appearance within the first 3 h of exposure
to CQ [9,64,67]. The initial autophagic response that we
observed, however, is probably a canonical form of autophagy
as it is SAR405-sensitive (Figure 7(C)) and induces ATG9A
puncta formation (Figure S9), rather than being the result of a
non-canonical LC3 conjugation on endosomes [29,49]. We
cannot exclude, however, that part of the cytoplasmic LC3
puncta that we detect might represent endosomes.
Importantly, the measurement of long-lived protein turnover
showed that the autophagic flux is also inhibited under the
same conditions. The fact that CQ did not stimulate autopha-
gic degradation at any time point over the course of the
treatments makes it different from the other inducers of
non-canonical autophagic pathways such as resveratrol or
gossypol, which enhance autophagic turnover [88].
Therefore, the initial autophagy induction triggered by CQ
that we and others observed [29,49], could also be due to
cellular stress that is caused by exposure to CQ rather than
stimulating a specific non-canonical autophagic pathway [89].
However, we cannot exclude differences between cell types
used in the experiments, and additional studies are needed to
decipher in detail the plethora of effects caused to cells by CQ.
The current clinical studies are aiming to determine
whether autophagy inhibition has a beneficial role in tumor
treatments [13,17,23–25]. Because CQ and HCQ are the only
FDA-approved drugs inhibiting autophagy, these compounds
have extensively been used to test whether the block of this
pathway improves tumor treatments. Our study, however,
underlines that although CQ and HCQ are indisputably
impairing the autophagic flux, their use entails multiple side
effects in vitro and in vivo, which include the disorganization
of the Golgi and endo-lysosomal networks, and even a tem-
porary induction of autophagic sequestration activity.
Therefore, positive effects on tumor regression by treatments
with CQ alone or in combination with other drugs that have
been observed in some clinical trials (NCT00969306) [24],
might not always be associated with a block in autophagy
[23,25]. Moreover, our data highlight that the interpretation
of results from clinical trials but also from in vivo and in vitro
studies in which CQ or HCQ has been used as an autophagy
inhibitor, have to consider that this compound leads to an
accumulation of autophagosomes rather than non-functional




The following primary antibodies were used: rabbit anti-LC3
(Novus Biologicals, NB600-1384), mouse anti-LC3
(Nanotools, 0231S0104), rabbit anti-LC3 (MBL international,
PM036), rabbit COPI delta (a kind gift from Catherine
Rabouille, Hubrecht Institute, Utrecht, The Netherlands),
mouse anti-TUBA4A/tubulin (Sigma, T5168), rabbit anti-
ATG13 (Sigma Aldrich, Sab4200100), rabbit anti-ATG7 (Cell
Signaling Technology, 2631), rabbit anti-phospho-EGFR
(Y1068; Cell Signaling Technology, 2234), mouse anti-actin
(Merck, MAB1501), rabbit anti-EGFR (Santa Cruz
Biotechnology, sc-03-G), guinea pig anti-SQSTM1/p62
(Progen, GP62-C) mouse anti-LAMP1 (BP Biosciences,
555798), mouse anti-LAMP2 (BD biosciences, 555803),
mouse anti-EEA1 (BD biosciences, 610456), mouse anti-
GOLGA2/GM130 (Abcam, ab52649), Armenian hamster
anti-ATG9L1 (Abcam, ab71795), mouse anti-TGOLN2/
TGN46 (SeroTec, AHP500) and mouse anti-M6PR (SeroTec,
MCA4333). The following secondary antibodies from
Invitrogen/Thermo Fisher Scientific were used for the visua-
lization of the primary antibodies: Alexa Fluor 488-conjugated
goat anti-mouse (A-11001) or chicken anti-rabbit (A-21441),
Alexa Fluor 568-conjugated goat anti-mouse (A-11031) or
goat anti-rabbit (A-11011), Alexa Fluor 647-conjugated goat
anti-mouse (A-21235), Alexa Fluor 680-conjugated goat anti-
mouse (A-21058) or goat anti-rabbit (A-21109). IRDYE 800-
conjugated goat anti-mouse (Rockland, 610-132-121) and
goat anti-Armenian hamster, FITC-conjugated (Jackson
ImmunoResearch Laboratories, 127-095-099). Prolong with
DAPI (P36931), LysoTracker Red (L7528) and BSA-TRITC
(A23016) were from Invitrogen/Thermo Fisher Scientific.
Hoechst33342 (B2261), pepstatin (P5318), leupeptin (L2884),
E64d (E3132), chloroquine (C6628) and hydroxychloroquine
(H0915) were from Sigma Aldrich, and bafilomycin A1 was
from BioAustralis (BIA-B1012). Torin 1 was from RnD
Systems (4247).
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Cell lines and cell culture
U2OS (a kind gift from Ger Strous, University Medical Center
Utrecht, The Netherlands), HeLa cells (a kind gift from Peter
van der Sluijs, Utrecht University, The Netherlands), HeLa-
RFP-GFP-LC3 cells (a kind gift from David C. Rubinsztein
and Tamotsu Yoshimori, Osaka University, Japan) [51], GFP-
SNAP29- and GFP-STX17-expressing MEFs (a kind gift from
N. Mizushima, University of Tokyo, Japan) [53], and MEFs (a
kind gift from I. Dikic, Goethe-Universität Frankfurt am
Main, Germany) were cultured in Dulbecco’s Modified Eagle
Medium (DMEM, Gibco, 31966-021) supplemented with
100 U/ml penicillin, 100 μg/ml streptomycin (Gibco,
15140-122) and 10% fetal calf serum, at 37°C in a 5%
CO2 humidified atmosphere. The culture medium of the
HeLa-RFP-GFP-LC3 cells was additionally supplemented
with 0.6 µg/ml G418 (Gibco, 11811-031).
Mice
Four- to 8-week-old female C57BL/6JOlaHsd mice were pur-
chased from Harlan Sprague Dawley Inc. (Indianapolis, IN,
USA). The mice were maintained under conventional condi-
tions and fed ad libitum with food pellets (RMH-B; Hope
Farms, Woerden, The Netherlands) and water. 60 mg/kg
HCQ (Sigma-Aldrich, H0915) [41] was administered by
daily intraperitoneal injections. The control group was
injected with a saline solution. The mice were sacrificed
24 h after the first or the second HCQ injection. All experi-
ments were approved and conducted in accordance with the
Ethics Committee on animal testing of the University of
Groningen.
Western-blot analyses
Cells grown in 6-well or 24-well plates were washed with
phosphate-buffered saline (PBS; 0.137 M NaCl, 0.027 M
KCl, 0.01 M Na2HPO4, 0.0018 M KH2PO4, pH 7.2)] and
harvested in 100 µl of lysis buffer (50 mM Tris, pH 7.6,
150 mM NaCl, 1% Triton-X100 [Sigma-Aldrich, 93443],
Complete protease inhibitor [Roche, 11836145001]). The
lysates were incubated on ice for 30 min, vortexed and cen-
trifuged at 14,000 g for 10 min at 4°C. The supernatants were
collected and mixed with Laemmli loading buffer [90].
Alternatively, cells were directly lysed in Laemmli loading
buffer and sonicated for 1 min. Equal protein amounts were
separated by SDS-PAGE and after standard western blot,
proteins were detected using specific antibodies and the
Odyssey Imaging System (LI-COR Biosciences, Lincoln, NE,
USA). Densitometric values were determined and quantified
on western blots at non-saturating exposures using the ImageJ
software [91], and normalized against the one of the tubulin
loading control.
Long-lived protein degradation assay
The assay was carried out as previously described [47] with
minor modifications. U2OS cells were seeded in a 24-well
plate in 0.5 ml culture medium supplemented with 0.1 µCi/
ml [14C]-L-valine (Vitrax, VC 308) for 2 days.
Unincorporated radioactivity was removed by washing each
well with culture medium supplemented with 10 mM L-valine
(Sigma Aldrich, V0500), and subsequently chased for 18–19 h
in the absence or presence of the indicated treatments in
culture medium supplemented with 10 mM L-valine. After
washing, cells were incubated for an additional 2 or 5 h with
the indicated compounds. Plates were cooled down on ice for
2 min before adding sequentially 50 µl of ice-cold PBS con-
taining 2% BSA (Sigma-Aldrich, A9418), and 200 µl of ice-
cold 25% trichloroacetic acid (TCA; Sigma Aldrich, T0699).
After overnight shaking at 4°C, mixtures from each well were
transferred into 1.5-ml microcentrifuge tubes and centrifuged
at 5,000 g for 10 min at 4°C. The TCA-soluble fractions (i.e.,
supernatants) were transferred to scintillation tubes and
mixed with 4 ml of Opti-Fluor (Perkin Elmer, 6013199) by
rigorous vortexing. The TCA-insoluble fractions in the micro-
centrifuge tubes (i.e., pellets) and in the wells both were
dissolved in 250 µl of 0.2 M KOH and combined, prior to
being transferred into scintillation tubes and mixed with 4 ml
Opti-Fluor by rigorous vortexing. Radioactivity in the TCA-
soluble and -insoluble fractions was measured by liquid scin-
tillation counting. The degradation rate for long-lived pro-
teins was calculated as the percentage of radioactivity in the
TCA-soluble fraction relative to the total radioactivity (i.e.,
TCA-soluble and -insoluble fractions), divided by the incuba-
tion time.
LDH sequestration assay
The assay was performed as previously described [45,47] with
minor modifications. U2OS cells were harvested by trypsini-
zation and resuspended in complete medium. After centrifu-
gation, the supernatant was aspirated, and the cells were
resuspended in 400 µl of 10% sucrose (Sigma-Aldrich,
S9378). The plasma membrane of the cells was selectively
disrupted using a custom-made electroporator (2000 V and
1.2 μF in a 1x1x5 cm electrode chamber), and then transferred
to new microcentrifuge tubes containing 400 μl of ice-cold
phosphate buffered sucrose (100 mM sodium monopho-
sphate, 2 mM dithiothreitol [DTT], 2 mM EDTA, 1.75%
sucrose, pH 7.5). Aliquots of these mixtures (100 µl) were
transferred to new microcentrifuge tubes and stored overnight
at −80°C to be used to measure the total amount of LDH in
the individual samples. In parallel, 500 µl of the same mixture
were also transferred to new microcentrifuge tubes and mixed
with 900 μl ice-cold resuspension buffer (50 mM sodium
monophosphate, pH 7.5, 1 mM EDTA, 1 mM DTT) supple-
mented with 0.5% BSA and 0.01% Tween 20 (Sigma-Aldrich,
93733), before centrifugation at 18,000 g for 45 min at 4°C.
The supernatant was subsequently aspirated and pellets stored
overnight at −80°C. The following day, the stored samples
were resuspended in 400 µl of ice-cold resuspension buffer
supplemented with Triton X-405 (Sigma Aldrich, X405) to a
final concentration of 1% (vol:vol). The amount of LDH in
each sample was quantified as the decline in NADH absor-
bance at 340 nM, using a multianalyzer (MaxMat PL-II, Erba
Diagnostics, Mannheim, Germany). The enzymatic reaction
was carried out in a buffer consisting of 65 mM imidazole, 0.6
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mM pyruvate, 0.36 mM NADH, pH 7.5. LDH sequestration
activity was calculated as percent of sedimentable LDH in
experimentally treated cells minus percent sedimentable
LDH in untreated control cells (background).
BSA uptake
U2OS or HeLa cells were seeded on glass coverslips in 24-well
plates before being pulsed with 375 nM BSA-TRITC for
30 min, thoroughly washed and incubated with medium with-
out BSA-TRITC for an additional 90 min. After this chasing
time, cells were treated with 100 µM CQ or 100 nM BafA1 for
5 h before being prepared for LAMP2 detection by immuno-
fluorescence. Alternatively, U2OS or HeLa cells were treated
with 100 µM CQ or 100 nM BafA1 for 2 h before incubation
with BSA-TRITC for 30 min. Again, the cells were thoroughly
washed and chased in the presence of 100 µM CQ or 100 nM
BafA1 for an additional 90 min before being prepared for
LAMP2 detection by immunofluorescence.
EGFR degradation and trafficking
HeLa cells were seeded in 24-wells plates on glass coverslips
for the EGFR trafficking or without coverslips for the EGFR
degradation assay. The cells were treated with 100 µM CQ or
100 nM BafA1 for 2 h before being incubated for 0, 5, 15, 30,
60, or 120 min with 50 ng/ml EGF (Thermo Fisher scientific,
E3477) or biotinylated EGF (Thermo Fisher scientific,
E35350), complexed to Alexa Fluor 555 Streptavidin
(Invitrogen/Thermo Fisher Scientific, S32355) for EGFR
degradation and trafficking, respectively. After the incubation,
cells were either lysed and analyzed by western-blot analysis
to determine EGFR and phosphorylated EGFR levels or fixed,
stained with anti-LAMP2 and analyzed for colocalization with
labeled EGF.
Immunofluorescence and fluorescence microscopy
Cells were fixed with 3.7% paraformaldehyde (PFA; Sigma
Aldrich, 441244) or 3.7% formaldehyde (Merck,
1040031000) or 100% methanol, washed and blocked with
blocking buffer (PBS, 1% bovine serum albumin, 0.1% sapo-
nin [Sigma-Aldrich, S4521]). Primary and secondary antibo-
dies were diluted in the blocking buffer and incubated for 1 h.
Nuclei were stained with Hoechst33342 and DAPI during the
incubation with the secondary antibody for automated image
acquisition and fluorescence microscopy, respectively. Mouse
kidneys and intestines were isolated and fixed with 4% for-
maldehyde and PFA, respectively, at room temperature over-
night. The tissues were processed using a tissue processing
machine (Leica TP 1200) before paraffin embedding. Paraffin
sections (3 µm) were cut, deparaffinized, rehydrated and
further heated in antigen retrieval buffer (10 mM citric acid
monohydrate [Sigma-Aldrich, C7129], pH 6.0, 10 mM
sodium citrate tribasic [Sigma-Aldrich, S4641]). The samples
were blocked in PBS, 1% goat serum (Jackson Immuno
Research Laboratories, 005–000-121), 0.4% Triton-X100 for
1 h prior to the primary antibody incubation in PBS, 0.1%
Tween 20 overnight at 4°C. Nuclei were stained with
Hoechst33342 during the incubation with the secondary anti-
body in the same buffer for 1 h. Fluorescence microscopy was
performed at room temperature using the DeltaVision RT
fluorescence microscope (Applied Precision Ltd., Issaquah,
WA, USA) equipped with a CoolSNAP HQ camera
(Photometrix, Kew, Australia). Images were generated by
collecting a stack of 6 to 16 images with focal planes 0.30-
μm apart, and subsequently deconvolved using the SoftWoRx
software (Applied Precision Ltd.). Quantification of puncta
number and size, and colocalization events of the acquired
images was performed using the Icy software (http://icy.bioi
mageanalysis.org) using spot detector plugin or the ImageJ
software.
siRna transfections
U2OS cells were transfected for 48 h with 20 nM of control
siRNA (D-001810-01-05) or of siRNA targeting ATG13 (J-
020765-12) or ATG7 (J-020112–08; all from Dharmacon)
using 0.1 µl or 2 µl of Lipofectamine RNAiMAX (Thermo
Fisher scientific, 13778150) for 96- or 6-well plate cultures,
respectively, according to the manufacturer’s protocol.
Automated image acquisition
A Cellomics Arrayscan VTI HCS Reader (Thermo Fisher
Scientific, Waltham, MA, USA) was used to acquire cell
images in the Hoechst, FITC, TRITC and Texas Red filters
using a the 20x lens for automated fluorescence signal
acquisition. The Cellomics SpotDetector V4 algorithm was
used to quantify the number and area of the detected
puncta in cells stained for SQSTM1, LAMP1, LysoTracker
Red, TGOLN2, M6PR and/or EEA1. The Hoechst channel
was used to set the autofocus. LAMP1, SQSTM1, M6PR,
TGOLN2 and EEA1 puncta were detected using the FITC
filter and LysoTracker Red puncta were detected using the
TexasRed filter. An equal fixed exposure time was automa-
tically set for all the samples. The numbers of nuclei (valid
object count), puncta per cell (spot per cell) and puncta
area per cell (spot area per cell) were counted using this
approach in each experiment. Alternatively, fluorescence
images of cells were automatically acquired using a
TissueFAXS (TissueGnostics, Vienna, Austria) that is
based on a high-end fully motorized Zeiss AxioObserver
Z1 microscope with a Zeiss-LD ‘Plan-Neofluar’ 20x/0.4
Corr Dry objective (Zeiss, Oberkochen, Germany). The
following filters were used: DAPI for the imaging of the
nuclei, GFP for the acquisition of the GOLGA2 and LAMP2
signals, Cy3 for the acquisition of the SQSTM1 signals and
TexasRed for the imaging of the LysoTracker Red. The
acquired images were analyzed using the TissueQuest fluor-
escence analysis software (TissueGnostics GmbH, Vienna,
Austria) to determine the cell count (based on the nuclei
staining). Quantification of the number of the imaged
puncta, and the colocalization degree of LAMP2 with




For conventional EM analyses, U2OS and HeLa cell lines were
treated for 1, 2 or 5 h with the indicated compounds before
being fixed in 2% PFA and 2.5% glutaraldehyde in 0.1 M
sodium cacodylate buffer (Sigma Aldrich, 20840-100G-F; pH
7.4) for 2 h at room temperature. Cells were subsequently
embedded in Epon resin (for 25 ml: 12 g glycid ether [Serva,
21045.02], 8 g 2-dodecenysuccinic- acid anhydride [Serva,
20755.02], 5 g methylnadic anhydride [Serva, 29452.02],
560 µl N-Benzyldimethylamine [EMS 11400-25]) as pre-
viously described [92]. Subsequently, 70-nm sections were
obtained using an UC7 ultramicrotome (Leica Microsystems,
Vienna, Austria) and stained with uranyl acetate and lead
citrate [92]. Cell sections were finally analyzed using an 80
kV CM100 transmission electron microscope (FEI,
Eindhoven, The Netherlands). Statistical analysis of the num-
ber of structures of interest per cell profile was performed by
randomly selecting and screening 100 cell sections from 2
independent grids.
For immuno-EM analyses, RFP-GFP-LC3 HeLa cells were
treated for 2 h with 100 µM CQ and then fixed by adding an
equal volume as the culture medium of 4% PFA and 0.4%
glutaraldehyde (Merck, 1042390250) in 0.1 M phosphate buf-
fer (19 mM NaH2PO4, 81 mM Na2HPO4, pH 7.4) for 20 min
at room temperature. Cells were then post-fixed in 2%
PFA:0.2% glutaraldehyde for 3 h also at room temperature
before being embedded following the Tokuyasu procedure
[93]. Ultrathin cryo-sections were cut, labeled for LAMP2
and subsequently with 10 nm immuno-gold as previously
described [93]. Cell sections were also examined using the
80 kV CM100 transmission electron microscope.
Statistical analyses
Statistical significance was evaluated using the two-tailed het-
eroscedastic t-test before calculating the p-values. Individual
data points from each independent experiment were used for
the calculation of the significance. The number of indepen-





EEA1: early endosome antigen 1
GOLGA2: golgin A2
HCQ: hydroxychloroquine
LAMP: lysosomal associated membrane protein;
M6PR: mannose-6-phosphate receptor, cation
dependent




TGOLN2: trans-golgi network protein 2
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